These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 6240552

  • 1. Combination therapy of murine tumors with a degraded D-manno-D-glucan (DMG) from Microellobosporia grisea, and cyclophosphamide.
    Nakajima H, Hashimoto S, Kita Y, Takashi T, Tsukada W, Kohno M, Ogawa H, Abe S, Mizuno D.
    Jpn J Exp Med; 1983 Dec; 53(6):263-9. PubMed ID: 6240552
    [Abstract] [Full Text] [Related]

  • 2. Potentiation of antitumor immunity in tumor-bearing mice by a degraded D-manno-D-glucan (DMG), a new antitumor polysaccharide.
    Nakajima H, Kita Y, Hashimoto S, Tsukada W, Abe S, Mizuno D.
    Jpn J Exp Med; 1983 Dec; 53(6):281-8. PubMed ID: 6680757
    [Abstract] [Full Text] [Related]

  • 3. Host-mediated antitumor effect of DMG, a degraded D-manno-D-glucan from Microellobosporia grisea culture fluid.
    Nakajima H, Hashimoto S, Nagao S, Kita Y, Khono M, Ogawa H, Abe S, Mizuno D.
    Gan; 1984 Mar; 75(3):253-9. PubMed ID: 6233200
    [Abstract] [Full Text] [Related]

  • 4. Immunopotentiation by a new antitumor polysaccharide, DMG, a degraded D-manno-D-glucan from Microellobosporia grisea culture fluid.
    Nakajima H, Kita Y, Takashi T, Akasaki M, Yamaguchi F, Ozawa S, Tsukada W, Abe S, Mizuno D.
    Gan; 1984 Mar; 75(3):260-8. PubMed ID: 6427053
    [Abstract] [Full Text] [Related]

  • 5. Elimination of tumor-enhancing cells by cyclophosphamide and its relevance to cyclophosphamide therapy of the murine mammary tumor.
    Nakajima H, Abe S, Masuko Y, Tsubouchi J, Yamazaki M, Mizuno D.
    Gan; 1981 Oct; 72(5):723-31. PubMed ID: 7327373
    [Abstract] [Full Text] [Related]

  • 6. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
    Nitta K, Tanaka T, Takeuchi M.
    Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
    [Abstract] [Full Text] [Related]

  • 7. Complete regression of Lewis lung carcinoma by cyclophosphamide in combination with immunomodulators.
    Abe S, Takahashi K, Yamazaki M, Mizuno D.
    Jpn J Cancer Res; 1985 Jul; 76(7):626-30. PubMed ID: 3928559
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of T suppressor cell function by local administration of an active cyclophosphamide derivative at the sensitization site.
    Limpens J, Scheper RJ.
    Clin Exp Immunol; 1991 Jun; 84(3):383-8. PubMed ID: 1828396
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy of murine tumors with lentinan plus lipopolysaccharide plus cyclophosphamide.
    Abe S, Tsubouchi J, Takahashi K, Yamazaki M, Mizuno D.
    Gan; 1982 Dec; 73(6):961-7. PubMed ID: 7160585
    [Abstract] [Full Text] [Related]

  • 10. The antitumor effect of postoperative treatment with genistein alone or combined with cyclophosphamide in mice bearing transplantable tumors.
    Wietrzyk J, Opolski A, Madej J, Radzikowski C.
    Acta Pol Pharm; 2000 Nov; 57 Suppl():5-8. PubMed ID: 11293263
    [Abstract] [Full Text] [Related]

  • 11. Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.
    Corbett TH, Griswold DP, Mayo JG, Laster WR, Schabel FM.
    Cancer Res; 1975 Jun; 35(6):1568-73. PubMed ID: 1131824
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions.
    Inagawa H, Nishizawa T, Honda T, Nakamoto T, Takagi K, Soma G.
    Anticancer Res; 1998 Jun; 18(5D):3957-64. PubMed ID: 9854510
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dependence on chain length of antitumor activity of (1 leads to 3)-beta-D-glucan from Alcaligenes faecalis var. myxogenes, IFO 13140, and its acid-degraded products.
    Sasaki T, Abiko N, Sugino Y, Nitta K.
    Cancer Res; 1978 Feb; 38(2):379-83. PubMed ID: 620409
    [Abstract] [Full Text] [Related]

  • 16. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R.
    J Immunol; 1998 Dec 15; 161(12):6977-84. PubMed ID: 9862733
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of cyclophosphamide on spleen cell suppressor activity and tumour growth in mice.
    Larsen FS, Spärck JV.
    Acta Pathol Microbiol Immunol Scand C; 1983 Oct 15; 91(5):323-33. PubMed ID: 6229132
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.